Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1508

Sort by

Sort Order Select

Journal Articles

Retinoids in hematology: a timely revival?

Marie-Claude Geoffroy, Cécile Esnault, Hugues de Thé

Blood (2021) 137 (18): 2429–2437.

https://doi.org/10.1182/blood.2020010100

Published: 2021

Journal Articles

A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia

Yun Tan, Xiaoling Wang, Huan Song, Yi Zhang, Rongsheng Zhang, Shufen Li, Wen Jin, Saijuan Chen, Hai Fang, Zhu Chen, Kankan Wang

Blood (2021) 137 (11): 1503–1516.

https://doi.org/10.1182/blood.2020005698

Published: 2021

Includes: Supplemental data

Journal Articles

Acute myeloid leukemia with NPM1 and FLT3 ITD mimicking acute promyelocytic leukemia

Michael Pepper, Brent Tan

Blood (2020) 136 (12): 1467.

https://doi.org/10.1182/blood.2020007198

Published: 2020

Journal Articles

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Blood (2020) 136 (7): 823–830.

https://doi.org/10.1182/blood.2019004583

Published: 2020

Includes: Supplemental data

Journal Articles

Promyelocytic leukemia with basophil-like granules

Elisa Piva, Francesca Tosato

Blood (2020) 136 (3): 372.

https://doi.org/10.1182/blood.2020006060

Published: 2020

Journal Articles

Norsworthy KJ, Bird ST, Avagyan A, et al. Second cancers in adults with acute promyelocytic leukemia (APL) treated with or without arsenic trioxide (ATO): a SEER-Medicare analysis [abstract]. Blood. 2019;134(suppl 1). Abstract 3497.

Blood (2020) 135 (23): 2111.

https://doi.org/10.1182/blood.2020006455

Published: 2020

Journal Articles

Microgranular acute promyelocytic leukemia with expression of T-cell markers mimicking mixed-phenotype acute leukemia

Wei Liu, Jie Xu

Blood (2020) 135 (11): 880.

https://doi.org/10.1182/blood.2019004434

Published: 2020

Journal Articles

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Ilaria Iacobucci, PhD, Manja Meggendorfer, PhD, Niroshan Nadarajah, Stanley Pounds, PhD, Lei Shi, PhD, Chunxu Qu, PhD, Constance Baer, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Charles G. Mullighan, MBBS, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2019-132746

Published: 2019

Journal Articles

The Impact of Diagnosis to Treatment Interval on the Outcome of Patients with Acute Myeloid Leukemia

Samah Nassereddine, MD, Kimberley Doucette, MD MSc, Vanya Aggarwal, Richard Amdur, PhD, Imad A. Tabbara, MD, Catherine E. Lai, MD

Blood (2019) 134 (Supplement_1): 2212.

https://doi.org/10.1182/blood-2019-124150

Published: 2019

Journal Articles

A Novel Chemical Compound Inhibiting Hematopoietic Cell Kinase (iHCK) Has a Synergic Effect with Azacytidine (Aza) or Cytarabine (Ara-C) for Acute Myeloid Leukemia Treatment

Fernanda Marconi Roversi, Maura Lima Pereira Bueno, undergraduate, Cristiane Okuda Torello, PhD, Fernanda I Della Via, MSc, Renata Giardini Rosa, PhD, Juares Ednaldo Romero Bianco, PhD, Adriana Silva Santos Duarte, PhD, Eduardo M Rego, MD PhD, Alessio Molinari, Maurizio Botta, Sara T Olalla Saad, PhD

Blood (2019) 134 (Supplement_1): 4650.

https://doi.org/10.1182/blood-2019-128959

Published: 2019

Journal Articles

Validation of the Revised AML-Composite Model for the Prediction of Prognosis in Older Patients Receiving Intensive Induction Therapy

Corentin Orvain, Aline Tanguy-Schmidt, Sylvain Thepot, MD, Anne Bouvier, Benedicte Ribourtout, Franck Genevieve, Aurelien Giltat, Marion Champire, Adeline Chanson, Marielle Subileau, Damien Luque Paz, Valerie Ugo, Norbert Ifrah, Mathilde Hunault, MD PhD

Blood (2019) 134 (Supplement_1): 1310.

https://doi.org/10.1182/blood-2019-127351

Published: 2019

Journal Articles

Comprehensive Characterization of Cytogenetic and Mutational Analysis of Acute Promyelocytic Leukemia: Is PML-Rara Everything?

Hassan Awada, MD, Jibran Durrani, Tariq Zuheir Kewan, MD, Ashwin Kishtagari, MBBS, Valeria Visconte, PhD, Reda Z. Mahfouz, MD PhD

Blood (2019) 134 (Supplement_1): 1404.

https://doi.org/10.1182/blood-2019-131724

Published: 2019

Journal Articles

Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

Blood (2019) 134 (Supplement_1): 1358.

https://doi.org/10.1182/blood-2019-125262

Published: 2019

Journal Articles

Towards Molecularly Informed Acute Myeloid Leukemia Subtyping Reflective of Pathogenesis

Hassan Awada, Arda Durmaz, Yasunobu Nagata, MD PhD, Teodora Kuzmanovic, Ashwin Kishtagari, MBBS, Jibran Durrani, Cassandra M Kerr, MS, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Tomas Radivoyevitch, PhD, Manja Meggendorfer, PhD, Aziz Nazha, MD, Valeria Visconte, PhD, Mikkael A. Sekeres, MD MS, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1406.

https://doi.org/10.1182/blood-2019-132031

Published: 2019

Journal Articles

A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Naval G. Daver, MD, Weiguo Zhang, MD PhD, Richard Graydon, MD PhD, Vikas K Dawra, MBA, PhD, Jingdong Xie, PhD, Prasanna Kumar, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1389.

https://doi.org/10.1182/blood-2019-122585

Published: 2019

Journal Articles

Asian Experience of Treating Venous Thromboembolism in Patients with Acute Leukaemia

Cheryl XQ Lim, MBBS, M MD(Int MD, MRCP, Priscella Shirley Chia, BSc, Eng Soo Yap, MBBS, M MD(Int MD, MRCP, FRCPath Haematology

Blood (2019) 134 (Supplement_1): 1161.

https://doi.org/10.1182/blood-2019-130041

Published: 2019

Journal Articles

Characterization of Recombinant β2GPI Using Hydrogen-Deuterium Exchange and X-Ray Crystallography

Ravi Kumar Alluri, PhD, Nicholas Arce, Philip Klenotic, Chih Chia Su, PhD, Suman Kundu, MBA, Edward Yu, PhD, Renhao Li, PhD, Keith R McCrae, MD

Blood (2019) 134 (Supplement_1): 1105.

https://doi.org/10.1182/blood-2019-131386

Published: 2019

Journal Articles

TP73 As Novel Determinant of Resistance to BCL-2 Inhibition in Acute Myeloid Leukemia

Yuki Nishida, MD PhD, Jo Ishizawa, MD PhD, Vivian Ruvolo, MS, Feng Wang, PhD, Koichi Takahashi, MD, Po Yee Mak, Bing Z Carter, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1251.

https://doi.org/10.1182/blood-2019-127182

Published: 2019

Journal Articles

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML): Princess Margaret Cancer Centre Experience

Muhned Alhumaid, MD, Georgina S Daher-Reyes, MD, Wilson Lam, MD, Arjun Law, MDDM, Tracy Murphy, MDFRCP,FRCPath, Caroline J McNamara, MBBS, Gil Yerushalmi, Aaron D Schimmer, MD PhD, Andre C. Schuh, MD, Dawn Maze, MDFRCPC,MSc, Eshetu G Atenafu, M.Sc., P.Stat, Karen W.L. Yee, MD, Mark D. Minden, MD PhD, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Hassan Sibai, MBBS

Blood (2019) 134 (Supplement_1): 2609.

https://doi.org/10.1182/blood-2019-125449

Published: 2019

Journal Articles

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Pau Montesinos, MD PhD, Maria Calbacho, MD, Jordi Sierra Gil, MD PhD, Jaime Perez De Oteyza, MD PhD, Jacob M. Rowe, MB, BS, Ofir Wolach, MD, Yishai Ofran, MD, Yakir Moshe, MD, Jichao Sun, PhD, Jan Baughman, MPH, Eileen McNulty, MS, Ezio Bonvini, MD, Jon M. Wigginton, MD, Jan K Davidson-Moncada, MD PhD

Blood (2019) 134 (Supplement_1): 2662.

https://doi.org/10.1182/blood-2019-125966

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Retinoids in hematology: a timely revival?

A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia

Acute myeloid leukemia with NPM1 and FLT3 ITD mimicking acute promyelocytic leukemia

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Promyelocytic leukemia with basophil-like granules

Norsworthy KJ, Bird ST, Avagyan A, et al. Second cancers in adults with acute promyelocytic leukemia (APL) treated with or without arsenic trioxide (ATO): a SEER-Medicare analysis [abstract]. Blood. 2019;134(suppl 1). Abstract 3497.

Microgranular acute promyelocytic leukemia with expression of T-cell markers mimicking mixed-phenotype acute leukemia

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

The Impact of Diagnosis to Treatment Interval on the Outcome of Patients with Acute Myeloid Leukemia

A Novel Chemical Compound Inhibiting Hematopoietic Cell Kinase (iHCK) Has a Synergic Effect with Azacytidine (Aza) or Cytarabine (Ara-C) for Acute Myeloid Leukemia Treatment

Validation of the Revised AML-Composite Model for the Prediction of Prognosis in Older Patients Receiving Intensive Induction Therapy

Comprehensive Characterization of Cytogenetic and Mutational Analysis of Acute Promyelocytic Leukemia: Is PML-Rara Everything?

Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

Towards Molecularly Informed Acute Myeloid Leukemia Subtyping Reflective of Pathogenesis

A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Asian Experience of Treating Venous Thromboembolism in Patients with Acute Leukaemia

Characterization of Recombinant β2GPI Using Hydrogen-Deuterium Exchange and X-Ray Crystallography

TP73 As Novel Determinant of Resistance to BCL-2 Inhibition in Acute Myeloid Leukemia

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML): Princess Margaret Cancer Centre Experience

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only